Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Ensitrelvir→

Ensitrelvir Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2647530-73-0
Molecular formula
C22H17ClF3N9O2
Molecular weight
531.88 g/mol
Drug class
Oral SARS-CoV-2 3-chymotrypsin-like protease (3CLpro/Mpro) inhibitorantiviral
Mechanism of action
Inhibits the SARS-CoV-2 main protease (3CLpro/Mpro), preventing cleavage of viral polyproteins required for replication and assembly of functional viral proteins.
Indications / reported uses
  • Post-exposure prophylaxis of COVID-19 in adults and adolescents aged 12 years and older under the EU-authorised ZOKOVEA indication (EU marketing authorisation issued 18 September 2026). Do not extrapolate this indication to treatment of established COVID-19 or other jurisdictions without a corresponding authorisation.

Sources: EMA EPAR — Zokovea, EU marketing authorisation 18 September 2026 · European Commission Union Register — Zokovea product indication · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Ensitrelvir Environmental Risk Assessment (ERA) (the Ensitrelvir ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.